Why Rheumatology Trials Fall Behind on Enrollment and How Patiro Solves It
Rheumatology enrollment slips for predictable reasons. Inclusion and exclusion criteria often hinge on prior biologic exposure, current disease activity scores, steroid and NSAID use, and comorbid autoimmune disease. Add fluctuating symptoms and imaging or lab requirements, and screen failure quickly rises.
Patients also carry real visit burden. Pain, fatigue, work disruption, and mobility limits make frequent on-site assessments hard to keep up over time. The sites may have awareness, but still lose momentum when follow-up is slow and pre-screening is too generic.
Patiro supports sponsors and CROs running rheumatology trials for drugs, devices, and procedures. We recruit to the protocol, not to clicks, and we stay close to sites so referrals, screening, and retention do not drift.
Patiro's Expertise in Rheumatology Clinical Trials
Rheumatology requires patient-facing messaging that acknowledges symptom variability and burden without softening the inclusion and exclusion details. We write and qualify to what the protocol actually needs, then localize by country, care pathway, and site workflow.
Patiro has supported immune-mediated and inflammatory indications that share the same recruitment realities as rheumatology: shifting disease activity, overlapping diagnoses, and complex background therapy. Experience includes Psoriasis, where a meaningful share of patients go on to develop psoriatic arthritis, and Ulcerative Colitis and Crohn's Disease, both closely linked to enteropathic arthritis and spondyloarthropathies. Additional experience includes Small Fiber Neuropathy, a common extra-articular manifestation of autoimmune rheumatologic disease.
Why Partner With Patiro for Your Rheumatology Trial?
Patiro runs global full-service and tailored FSP support across patient recruitment and site-facing execution. We report on what sources are producing screened, randomized, and enrolled patients so you can make decisions before timelines slip.
Patiro offers a Pay Only per Enrolled Patient-pricing model. This matters in rheumatology where strict criteria and fluctuating activity can drive screen failure. Across programs, this approach has delivered 40% faster recruitment timelines and a 65% reduction in patient attrition rates based on case studies.
Contact us to discuss how we can help with clinical trial recruitment for your rheumatology trial.
Frequently Asked Questions
Who does Patiro support in rheumatology clinical trial recruitment?
Sponsors and CROs who need enrollment support for rheumatology trials across medications, devices, and procedures.
How does Patiro reduce rheumatology screening failure?
We build protocol-specific outreach and structured pre-screening, then optimize based on site feedback and screening outcomes.
Can Patiro support retention as well as recruitment?
Yes. We plan participant communication and site follow-up from the start to reduce missed visits and dropouts.
What do you need to start?
Protocol summary, inclusion and exclusion criteria, target countries, enrollment targets, timelines, and site list if selected.
How does pricing work for rheumatology trials?
Sponsors pay per enrolled patient with Patiro, not per referral generated. That structure limits budget exposure on your end and gives us a direct stake in reaching your actual enrollment target, not just driving volume into the funnel.
How fast can you start rheumatology patient recruitment?
How fast we can start rheumatology patient recruitment comes down to a couple things: how well-defined the protocol is, which countries are involved, and whether the site plan is settled. We move quickly the moment pre-screening criteria and referral pathways are locked in. Across other therapeutic areas, we have also stepped into studies mid-course to rescue enrollment that had stalled, so fast starts without sacrificing referral quality is territory we know well.
